Author(s): Saranya M, Punnagai K, Darling Chellathai David, Anusha D

Email(s): punnagai.k@sriramcahndra.edu.in

DOI: 10.5958/0974-360X.2020.00014.1   

Address: Saranya M1, Punnagai K2, Darling Chellathai David3, Anusha D4
Demonstrator, Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu
Professor and Head, Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu
Professor, Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu
Associate Professor, Department of Pharmacology, Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu
*Corresponding Author

Published In:   Volume - 13,      Issue - 1,     Year - 2020


ABSTRACT:
Cancer are described by uncontrolled cell growth. In the world colorectal cancer is been categorized as third most common cancer. In this study the effects of tolvaptan on the cell viability in human HT-29 cells is been explored. Tolvaptan blocks the vasopressin receptor. This drug also inhibits mitogenic effects of vasopressin on its receptors. We propose this drug might have antiproliferative and cytotoxic effects in tumour cell lines like HT-29. Tolvaptan treatment decreases cyclins and cyclin-dependent kinases in the cells. Imatinib acts by inhibiting some selective tyrosine kinase which considered to be involved in the pathogenesis of chronic myeloid leukemia. Imatinib is used in gastrointestinal tumors that express tyrosine kinase. Aim: To elucidate the anticancer activate using Invitro -MTT assay of Tolvaptan in comparison with imatinib on colorectal cell lines. Cell line and culture: HT-29 cell line was obtained from Veterinary College, Vepery, and Chennai. Reagents: “All the chemicals and reagents were obtained from Sigma Aldrich Mumbai. In Vitro assay for anticancer activity (MTT assay) were performed and the concentration required for a 50% inhibition (IC50) was determined graphically. The % cell viability was calculated using the following formula: % cell viability = A570 of treated cells / A570 of control cells × 100” The anticancer effect of tolvaptan and imatinib were treated on HT-29 cell line starting minimum to maximum dose concentration (µg/ml), the cell viability percentage was seen. Hence the maximum cell viability percentage of tolvaptan is 64.77% (minimum cell inhibition 35.23%) seen at 7.8(µg/ml) whereas the minimum cell viability of tolvaptan is 1.42% (maximum cell inhibition is 98.58%) observed at 1000(µg/ml, In Imatinib Maximum cell viability is 67.61% (minimum cell inhibition-32.39%) and minimum cell viability is 2.55 % (maximum cell inhibition -97.45) Conclusion: From the study, we conclude that tolvaptan has cell inhibitory activity on the growth of HT-29 colon carcinoma cell line, when compared with a imatinib as a control which acts as a potent anticancer. The additional effects of this drug can be proved further studies are required.


Cite this article:
Saranya M, Punnagai K, Darling Chellathai David, Anusha D. Evaluation of Anticancer Effects of Vasopressin Receptor blocker in Colon Cancer – An In vitro Study. Research J. Pharm. and Tech. 2020; 13(1):77-80. doi: 10.5958/0974-360X.2020.00014.1

Cite(Electronic):
Saranya M, Punnagai K, Darling Chellathai David, Anusha D. Evaluation of Anticancer Effects of Vasopressin Receptor blocker in Colon Cancer – An In vitro Study. Research J. Pharm. and Tech. 2020; 13(1):77-80. doi: 10.5958/0974-360X.2020.00014.1   Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-1-14


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available